BamSEC and AlphaSense Join Forces
Learn More

Opus Genetics Inc.

NASDAQ: IRD    
Share price (12/26/24): $1.08    
Market cap (12/26/24): $34.1 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 2 pages Second Amendment to Ocuphire Pharma, Inc. 2021 Inducement Plan
12/34/56
EX-10.2
from 10-Q 25 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 42 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Ocuphire Pharma, Inc. Third Amended and Restated Non-Employee Director Compensation Policy Effective Date: June 11, 2024
12/34/56
EX-10.1
from 10-Q 1 page Amendment No. 3 to Consulting Agreement
12/34/56
EX-10.1
from 8-K 23 pages Consulting Agreement
12/34/56
EX-10.5-5
from 10-K 2 pages Fifth Lease Amendment
12/34/56
EX-10.2
from 8-K 3 pages First Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 16 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 5 pages First Amendment to Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 20 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 9 pages November 17, 2023 Dear Joe, We Are Pleased to Offer You Employment With Ocuphire Pharma, Inc., a Delaware Corporation (The “Company”). the Terms of Your Offer of Employment With the Company Are as Follows
12/34/56
EX-10.3
from 8-K 1 page First Amendment to Ocuphire Pharma, Inc. 2021 Inducement Plan
12/34/56
EX-10.2
from 8-K 9 pages Ocuphire Pharma, Inc. Rsu Award Grant Notice
12/34/56
EX-10.1
from 8-K 21 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 14 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 48 pages Purchase Agreement
12/34/56
EX-10.3
from 10-Q 8 pages Separation and Release Agreement
12/34/56
EX-10.2
from 10-Q 6 pages Ocuphire Pharma, Inc. Second Amended and Restated Non-Employee Director Compensation Policy Effective Date: January 1, 2023
12/34/56
EX-10.1
from 10-Q 3 pages Richard Rodgers Re: Ocuphire Pharma, Inc. Interim President and CEO Consulting Letter Agreement Dear Richard
12/34/56